$BCLI News

BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Brainstorm Cell Q2 EPS $(0.35) Down From $(0.34) YoY

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts As Board Director

BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Brainstorm Cell Q1 EPS $(0.19) Beats $(0.36) Estimate

BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

Brainstorm Cell Q4 EPS $(0.20) Beats $(0.37) Estimate

Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February

Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market

BrainStorm Cell Therapeutics Announces $1M Strategic Private Placement Priced At $0.60 Per Share With 120% Warrant Coverage At $1.00 To Support NurOwn Phase 3b ALS Trial And Regulatory Initiatives

BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Brainstorm Cell Q3 EPS $(0.19) Beats $(0.37) Estimate

BCLI: Focused on Initiation of Phase 3b ENDURANCE Trial of NurOwn® in ALS…

Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2025 Earnings Call Transcript

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update